{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:03:02Z","timestamp":1768413782344,"version":"3.49.0"},"reference-count":20,"publisher":"Japan Epidemiological Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Epidemiology"],"published-print":{"date-parts":[[2012]]},"DOI":"10.2188\/jea.je20110101","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T22:43:08Z","timestamp":1340145788000},"page":"370-374","source":"Crossref","is-referenced-by-count":5,"title":["Descriptive Epidemiology of Fabry Disease Among Beneficiaries of the Specified Disease Treatment Research Program in Japan"],"prefix":"10.2188","volume":"22","author":[{"given":"Kazuya","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadao","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"991","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nagueh SF. Fabry disease. Heart. 2003;89:819–20.","DOI":"10.1136\/heart.89.8.819"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427–35.","DOI":"10.1016\/S0140-6736(08)61589-5"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1086\/504601"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01309.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750–60.","DOI":"10.1136\/jmg.38.11.750"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fabry H. Angiokeratoma corporis diffusum—Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy. Acta Paediatr Suppl. 2002;91:3–5.","DOI":"10.1080\/080352502762457824"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009;4:21.","DOI":"10.1186\/1750-1172-4-21"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1159\/000250968"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Porsch DB, Nunes AC, Milani V, Rossato LB, Mattos CB, Tsao M, et al. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report. Ren Fail. 2008;30:825–30.","DOI":"10.1080\/08860220802353777"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gaspar P, Herrera J, Rodrigues D, Cerezo S, Delgado R, Andrade CF, et al. Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet. 2010;11:19.","DOI":"10.1186\/1471-2350-11-19"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.558320"},{"key":"12","unstructured":"12. Nanbyou.or.jp. The Specified Disease Treatment Research Program (“Tokutei Shikkan Chiryo Kenkyu Jigyo”) [cited 2010 Sep 6]. Available from: http:\/\/www.nanbyou.or.jp\/."},{"key":"13","unstructured":"13. Moran V, Obrador GT, Thadhani R. Fabry kidney disease. Saudi J Kidney Dis Transpl. 2003;14:367–77."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Verovnik F, Benko D, Vujkovac B, Linthorst GE. Remarkable variability in renal disease in a large Slovenian family with Fabry disease. Eur J Hum Genet. 2004;12:678–81.","DOI":"10.1038\/sj.ejhg.5201184"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67635-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288–93.","DOI":"10.1056\/NEJM199508033330504"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tanaka M, Ohashi T, Kobayashi M, Eto Y, Miyamura N, Nishida K, et al. Identification of Fabry’s disease by the screening of α-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol. 2005;64:281–7.","DOI":"10.5414\/CNP64281"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, et al. Quality of life of patients with Fabry disease. Qual Life Res. 2002;11:317–27.","DOI":"10.1023\/A:1015511908710"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res. 2002;11:127–33.","DOI":"10.1023\/A:1015009210639"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2009.01345.x"}],"container-title":["Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jea\/22\/4\/22_JE20110101\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T01:57:01Z","timestamp":1656554221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jea\/22\/4\/22_JE20110101\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2188\/jea.je20110101","relation":{},"ISSN":["0917-5040","1349-9092"],"issn-type":[{"value":"0917-5040","type":"print"},{"value":"1349-9092","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}